Companies ›Healthcare ›MVP.AX

MVP.AX — ASX Pharmaceuticals

Medical Developments International Ltd

A$0,39

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

43,4M AUD

P/E

467,4x

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Medical Developments International Ltd is a pharmaceutical company that develops and commercializes medical devices and products, primarily in the healthcare sector.

Business. Medical Developments International Ltd (MVP.AX) is a pharmaceutical company listed on the Australian Securities Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target0,85

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

0,85

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

1 analysts · indicative

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MVP.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to MVP.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Medical Developments International Ltd (MVP.AX) is a pharmaceutical company listed on the Australian Securities Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

Medical Developments International Ltd has a market capitalization of AUD 43.94 million, with a current market price of AUD 0.39 per share. The company has 112,658,324 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and returns are not quantifiable at this time, as no financial metrics such as return on invested capital (ROIC), gross margins, or net margins are available in the valuation snapshot. Analysts have provided a mean price target of AUD 0.85, with a median and high target also at AUD 0.85, suggesting a consensus on potential upside.

Segment and geographic exposure data are not disclosed in the available information, making it difficult to assess revenue concentration or geographic diversification. The company's business is described as being in the pharmaceuticals industry, but no specific segments or regions are identified.

Growth trajectory is not clearly defined in the available data. Analysts have issued one "buy" recommendation and no "strong buy" or "hold" ratings, indicating a cautious but not enthusiastic outlook. No specific revenue growth rates or future financial projections are provided in the input data.

The company's risk profile includes a low dilution potential, as no significant dilution sources are identified in the risk assessment. However, liquidity risk remains unassessed due to the lack of balance-sheet data and no going-concern language in source documents.

Recent events or filings are not detailed in the input data, and no transcripts or disclosures are available to provide insight into the company's recent operations or strategic direction.

Key takeaways

The company has a low dilution risk, with no significant dilution sources identified.
Analysts have provided a consistent price target of AUD 0.85, suggesting a potential upside from the current market price.
Liquidity risk could not be assessed due to the absence of balance-sheet data and no going-concern language in source documents.
No financial metrics such as ROIC or margins are available, making it difficult to assess profitability and returns.
The company's growth trajectory and revenue concentration are not clearly defined in the available data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2025-08-21

FY 2025 · Full-year highlights

Revenue A$39.1M, +17,8% YoY; Operating income +94,7% YoY.

RevenueA$39.1M+17,8 % YoY

Operating income-A$1.8M+94,7 % YoY

Net incomeA$94.0k+100,2 % YoY

Free cash flowA$2.3M+105,5 % YoY

EPS—

Operating cash flow-A$43.0k+99,6 % YoY

Financials

Income statement

RevenueA$39.1M

Gross profitA$29.4M

Operating income-A$1.8M

Net incomeA$94.0k

Margins

Gross margin75.3%

Operating margin-4.5%

Net margin0.2%

FCF margin5.8%

Balance sheet

Total assetsA$66.4M

Total liabilitiesA$11.3M

Total equityA$55.1M

Cash & equivalentsA$17.8M

Long-term debtA$2.0M

Cash flow

Operating cash flow-A$43.0k

CapEx-A$1.0M

Free cash flowA$2.3M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue A$39.1M, +17,8% YoY
▍Operating income +94,7% YoY
▍Net income +100,2% YoY
▍Free cash flow +105,5% YoY
▍Net margin 0.2%

Valuation FY

Market price

A$0,39

Market cap

A$43.9M

Enterprise valueⓘ

—

P/Eⓘ

467.4x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,01

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-08 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,01
Revenue	—no estimate	—no estimate	43,6M AUD
Operating income	—no estimate	—no estimate	-1,7M AUD

Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price targetA$0,85 · Median A$0,85

Low A$0,85High A$0,85

Operating income · consensus-1,7M AUD

EPS surprise

+671,4 %

reported vs consensus · beat

Revenue surprise

−10,4 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$0,85

MeanA$0,85

MedianA$0,85

HighA$0,85

SpotA$0,39

+120.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Medical Developments International Ltd Market data — financials · 2026-05-28
Medical Developments International Ltd Market data — analyst estimates · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MVP.AXCanonical

ASX · AUD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2025-08-21 04:29 UTCEARNINGSAnnual results — FY 2025 Revenue AUD 39.1M · Net AUD 0.1M

2023-08-31 03:39 UTCEARNINGSAnnual results — FY 2023 Revenue AUD 32.3M · Net AUD -5.6M

2022-08-04 05:01 UTCEARNINGSAnnual results — FY 2022 Revenue AUD 21.9M · Net AUD -12.4M

2021-08-25 04:16 UTCEARNINGSAnnual results — FY 2021 Revenue AUD 25.3M · Net AUD -12.6M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread